156 related articles for article (PubMed ID: 34207556)
1. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival.
Li W; Amei A; Bui F; Norouzifar S; Lu L; Wang Z
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207556
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
Lu L; Huang H; Zhou J; Ma W; Mackay S; Wang Z
BMC Cancer; 2019 Apr; 19(1):387. PubMed ID: 31023256
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
5. Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling.
Nguyen BQT; Tran TPD; Nguyen HT; Nguyen TN; Pham TMQ; Nguyen HTP; Tran DH; Nguyen V; Tran TS; Pham TN; Le MT; Phan MD; Giang H; Nguyen HN; Tran LS
Front Immunol; 2023; 14():1251603. PubMed ID: 37731488
[TBL] [Abstract][Full Text] [Related]
6. Interplay of tRNA-Derived Fragments and T Cell Activation in Breast Cancer Patient Survival.
Shan N; Li N; Dai Q; Hou L; Yan X; Amei A; Lu L; Wang Z
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32785169
[TBL] [Abstract][Full Text] [Related]
7. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
8.
Jian X; Xu L; Zhao J; Wang Y; Zhou W; Xie L
Mol Ther Nucleic Acids; 2022 Sep; 29():285-295. PubMed ID: 35950215
[TBL] [Abstract][Full Text] [Related]
9. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK
Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974
[TBL] [Abstract][Full Text] [Related]
10. Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.
Zhou C; Wei Z; Zhang L; Yang Z; Liu Q
Front Oncol; 2020; 10():593989. PubMed ID: 33363023
[TBL] [Abstract][Full Text] [Related]
11. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
12. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Zhou S; Liu S; Zhao L; Sun HX
Front Oncol; 2022; 12():786438. PubMed ID: 35387130
[TBL] [Abstract][Full Text] [Related]
14. Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.
Chaudhry Z; Boyadzhyan A; Sasaninia K; Rai V
Antibodies (Basel); 2024 Jun; 13(2):. PubMed ID: 38920970
[TBL] [Abstract][Full Text] [Related]
15. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
16. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy.
Mauriello A; Zeuli R; Cavalluzzo B; Petrizzo A; Tornesello ML; Buonaguro FM; Ceccarelli M; Tagliamonte M; Buonaguro L
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756926
[TBL] [Abstract][Full Text] [Related]
17. A novel neoantigen discovery approach based on chromatin high order conformation.
Shi Y; Zhang M; Meng L; Su X; Shang X; Guo Z; Li Q; Lin M; Zou X; Luo Q; Yu Y; Wu Y; Da L; Cai TW; He G; Han ZG
BMC Med Genomics; 2020 Aug; 13(Suppl 6):62. PubMed ID: 32854726
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing heterologous T-cell immunity and neoantigen immunogenicity.
Leng Q; Tarbe M; Long Q; Wang F
Clin Transl Immunology; 2020; 9(3):e01111. PubMed ID: 32211191
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
20. Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.
Kato T; Matsuda T; Ikeda Y; Park JH; Leisegang M; Yoshimura S; Hikichi T; Harada M; Zewde M; Sato S; Hasegawa K; Kiyotani K; Nakamura Y
Oncotarget; 2018 Feb; 9(13):11009-11019. PubMed ID: 29541393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
